Harpoon Therapeutics (NASDAQ:HARP) Upgraded to Hold by Zacks Investment Research

Zacks Investment Research upgraded shares of Harpoon Therapeutics (NASDAQ:HARP) from a sell rating to a hold rating in a report released on Thursday morning, Zacks.com reports.

According to Zacks, “Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company developing a novel class of T cell engagers which harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. Using its proprietary Tri-specific T cell Activating Construct(TM) platform, they are developing a pipeline of novel T cell engagers, focused on the treatment of solid tumors and hematologic malignancies. Harpoon Therapeutics Inc. is based in San Francisco, United States. “

A number of other research firms have also recently issued reports on HARP. Canaccord Genuity started coverage on shares of Harpoon Therapeutics in a research report on Tuesday, March 5th. They set a buy rating and a $24.00 price objective on the stock. Citigroup reissued a buy rating and set a $23.00 price objective on shares of Harpoon Therapeutics in a research report on Friday, May 24th. Robert W. Baird started coverage on shares of Harpoon Therapeutics in a research report on Monday, April 22nd. They set an outperform rating and a $25.00 price objective on the stock. Svb Leerink reissued an outperform rating on shares of Harpoon Therapeutics in a research report on Tuesday, March 5th. Finally, Wedbush started coverage on shares of Harpoon Therapeutics in a research report on Tuesday, March 5th. They set an outperform rating and a $23.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has an average rating of Buy and an average target price of $23.75.

HARP stock opened at $11.89 on Thursday. The stock has a market cap of $289.72 million and a PE ratio of -0.46. Harpoon Therapeutics has a 1 year low of $9.07 and a 1 year high of $17.85.

Harpoon Therapeutics (NASDAQ:HARP) last released its quarterly earnings data on Thursday, March 14th. The company reported ($8.15) earnings per share (EPS) for the quarter. The firm had revenue of $1.06 million for the quarter, compared to the consensus estimate of $1.22 million. On average, research analysts forecast that Harpoon Therapeutics will post -2.78 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Fosun International Ltd bought a new position in Harpoon Therapeutics in the 1st quarter valued at about $3,062,000. New Leaf Venture Partners L.L.C. bought a new position in Harpoon Therapeutics in the 1st quarter valued at about $27,666,000. Finally, MPM Asset Management LLC bought a new position in Harpoon Therapeutics in the 1st quarter valued at about $39,796,000. 54.14% of the stock is currently owned by institutional investors and hedge funds.

Harpoon Therapeutics Company Profile

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer.

Recommended Story: Trade Deficit

Get a free copy of the Zacks research report on Harpoon Therapeutics (HARP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Harpoon Therapeutics (NASDAQ:HARP)

Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.